Frank A J A Bodewes


Affiliation: University Medical Center Groningen
Country: The Netherlands


  1. Bodewes F, van der Wulp M, Beharry S, Doktorova M, Havinga R, Boverhof R, et al. Altered intestinal bile salt biotransformation in a cystic fibrosis (Cftr-/-) mouse model with hepato-biliary pathology. J Cyst Fibros. 2015;14:440-6 pubmed publisher
    ..Our findings suggest Cftr dependent, alterations in intestinal bacterial biotransformation of bile salts. ..
  2. Bodewes F, Verkade H, Taminiau J, Borowitz D, Wilschanski M. Cystic fibrosis and the role of gastrointestinal outcome measures in the new era of therapeutic CFTR modulation. J Cyst Fibros. 2015;14:169-77 pubmed publisher
  3. Borowitz D, Lubarsky B, Wilschanski M, Munck A, Gelfond D, Bodewes F, et al. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor. Dig Dis Sci. 2016;61:198-207 pubmed publisher
    ..Significant CFQ-R improvements were seen in perception of eating, body image, and sense of ability to gain weight. Nutritional status improved following treatment with ivacaftor for 48 weeks. ..
  4. Bodewes F, Verkade H, Wilschanski M. Gastroenterological endpoints in drug trials for cystic fibrosis. Pediatr Pulmonol. 2016;51:S18-S22 pubmed publisher
    ..Pediatr Pulmonol. 2016;51:S18-S22. © 2016 Wiley Periodicals, Inc. ..
  5. Bodewes F, Wouthuyzen Bakker M, Bijvelds M, Havinga R, de Jonge H, Verkade H. Ursodeoxycholate modulates bile flow and bile salt pool independently from the cystic fibrosis transmembrane regulator (Cftr) in mice. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1035-42 pubmed publisher
    ..Chronic UDCA treatment reduces the hydrophobicity of the bile salt pool in Cftr(-/-) mice. These results support a potential beneficial effect of UDCA on bile flow and bile salt metabolism in cystic fibrosis conditions...